It is proposed that the inhibition of the AT1R, and its down-stream signaling through IL-6, could provide a promising treatment avenue for breast cancer, utilizing a well-characterized and tolerated class of ARB/ACEI drugs. Here, IL6 is linked to breast carcinoma.